Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02338050 | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 1 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Sep 16, 2015 | clinicaltrials |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 2 | 7 | Cellectar Biosciences, Inc.INDUSTRY | 1 |
| Sep 9, 2015 |
| clinicaltrials |
| NCT01057212 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00498914 | Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects | terminated | Phase 2 | 41 | Astellas Pharma IncINDUSTRY | 4 | Sep 4, 2015 | clinicaltrials |
| NCT00983047 | Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer | terminated | Phase 2 | 30 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01119794 | Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab | terminated | Phase 2 | 10 | Brown UniversityOTHER | 1 | Aug 26, 2015 | clinicaltrials |
| NCT00954005 | Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma(R-GO) | terminated | Phase 1 / Phase 2 | 56 | German Low Grade Lymphoma Study GroupOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00391586 | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung | terminated | Phase 2 | 45 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 17, 2015 | clinicaltrials |
| NCT01009203 | Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma | terminated | Phase 2 | 13 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00871546 | SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) | terminated | Phase 2 | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 7, 2015 | clinicaltrials |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00250718 | Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | terminated | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT00363779 | Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01517776 | Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents(HGG-CilMetro) | terminated | Phase 2 | 28 | Martin-Luther-Universität Halle-WittenbergOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | terminated | Phase 2 | 23 | University of California, San FranciscoOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01497275 | Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 5 | Duke UniversityOTHER | 1 | Jul 15, 2015 | clinicaltrials |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(ALLPhi) | terminated | Phase 1 / Phase 2 | 8 | Rony SchaffelOTHER | 0 | Jul 9, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00358982 | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 51 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 3, 2015 | clinicaltrials |
| NCT01808534 | Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors | terminated | Phase 2 | 5 | Indiana UniversityOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00543582 | MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma | terminated | Phase 2 | 23 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00413478 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2015 | clinicaltrials |
| NCT01016795 | Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma(SCF980266) | terminated | Phase 2 | 32 | Aalborg University HospitalOTHER | 4 | Jun 25, 2015 | clinicaltrials |
| NCT00771602 | Alemtuzumab + Rituximab Consolidation in CLL | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01175772 | Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | terminated | Phase 2 | 6 | HaEmek Medical Center, IsraelOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01694576 | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation | terminated | Phase 2 | 10 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00718809 | Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01204788 | Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia | terminated | Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | terminated | Phase 2 | 29 | University Hospital, GhentOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT02022358 | Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? | terminated | Phase 2 | 34 | University College, LondonOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00431613 | Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 38 | Hellenic Oncology Research GroupOTHER | 1 | May 29, 2015 | clinicaltrials |
| NCT01397149 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | terminated | Phase 1 / Phase 2 | 4 | University of UlmOTHER | 2 | May 28, 2015 | clinicaltrials |
| NCT02310997 | Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)(MAC UCBT) | terminated | Phase 2 | 11 | University College, LondonOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT01200797 | SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | terminated | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT01038752 | Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | terminated | Phase 2 | 14 | Optimum Therapeutics, LLCINDUSTRY | 1 | May 21, 2015 | clinicaltrials |
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | terminated | Phase 2 | 13 | Stanford UniversityOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | Mirati Therapeutics Inc.INDUSTRY | 3 | May 8, 2015 | clinicaltrials |
| NCT00262925 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2015 | clinicaltrials |
| NCT01392170 | Pegasys in Patients With Chronic Myeloid Leukemia (CML) | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT00974662 | Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Steba Biotech S.A.OTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00073450 | Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) | terminated | Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 21, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2015source: clinicaltrials